Back to Authors

Guella, Ilaria

Mayo Clinic

University of British Columbia

Citations 2

α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease
Guella, Ilaria, Evans, Daniel M. , Szu‐Tu, Chelsea , Nosova, Ekaterina , Bortnick, Stephanie, Group, SNCA Cognition Study, Goldman, Jennifer G. , Dalrymple‐Alford, John C. , Geurtsen, Gert J. , Litvan, Irene , Ross, Owen A. , Middleton, Lefkos , Farrer, Matthew J. , Group, SNCA Cognition Study, Parkkinen, Laura , Goldman, Jennifer G , Ross, Owen A , Dalrymple-Alford, John C , Geurtsen, Gert J , Litvan, Irene

Annals of Neurology | April 19, 2016 | Volume: 79 | Issue: 6 | Pages: 991-999

10.1002/ana.24664 Get It

ObjectiveThe relationship between Parkinson disease (PD), PD with dementia (PDD), and dementia with Lewy bodies (DLB) has long been debated. Although PD is primarily considered a motor disorder, cognitive impairment is often present at diagnosis, and only ∼20% of patients remain cognitively intact in the long term. Alpha‐synuclein (SNCA) was first implicated in the pathogenesis of the disease when point mutations and locus multiplications were identified in familial parkinsonism with dementia. In worldwide populations, SNCA genetic variability remains the most reproducible risk factor for idiopathic PD. However, few investigators have looked at SNCA variability in terms of cognitive outcomes.MethodsWe have used targeted high‐throughput sequencing to characterize the 135kb SNCA locus in a large multinational cohort of patients with PD, PDD, and DLB and healthy controls.ResultsAn analysis of 43 tagging single nucleotide polymorphisms across the SNCA locus shows 2 distinct association profiles for symptoms of parkinsonism and/or dementia, respectively, toward the 3′ or the 5′ of the SNCA gene. In addition, we define a specific haplotype in intron 4 that is directly associated with PDD. The PDD risk haplotype has been interrogated at single nucleotide resolution and is uniquely tagged by an expanded TTTCn repeat.InterpretationOur data show that PD, PDD, and DLB, rather than a disease continuum, have distinct genetic etiologies albeit within one genomic locus. Such results may serve as prognostic biomarkers to these disorders, to inform physicians and patients, and to assist in the design and stratification of clinical trials aimed at disease modification. Ann Neurol 2016;79:991–999
Defining neurodegeneration on Guam by targeted genomic sequencing
Steele, John C., Guella, Ilaria, Szu‐Tu, Chelsea , Lin, Michelle K., Thompson, Christina, Evans, Daniel M. , Sherman, Holly E., Vilariño‐Güell, Carles , Gwinn, Katrina , Morris, Huw R. , Farrer, Matthew J. , Dickson, Dennis W. , Morris, Huw R

Annals of Neurology | January 5, 2015 | Volume: 77 | Issue: 3 | Pages: 458-468

10.1002/ana.24346 Get It

ObjectiveAmyotrophic lateral sclerosis/parkinsonism–dementia complex has been described in Guam, Western Papua, and the Kii Peninsula of Japan. The etiology and pathogenesis of this complex neurodegenerative disease remains enigmatic.MethodsIn this study, we have used targeted genomic sequencing to evaluate the contribution of genetic variability in the pathogenesis of amyotrophic lateral sclerosis, parkinsonism, and dementia in Guamanian Chamorros.ResultsGenes previously linked to or associated with amyotrophic lateral sclerosis, parkinsonism, dementia, and related neurodegenerative syndromes were sequenced in Chamorro subjects living in the Mariana Islands. Homozygous PINK1 p.L347P, heterozygous DCTN1 p.T54I, FUS p.P431L, and HTT (42 CAG repeats) were identified as pathogenic mutations.InterpretationThe findings explain the clinical, pathologic, and genetic heterogeneity observed in some multi‐incident families and contribute to the excess incidence of neurodegeneration previously reported on Guam. Ann Neurol 2015;77:458–468